Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $49
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Allison Bratzel maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $40 to $49.
Piper Sandler analyst Allison Bratzel maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $40 to $49.